Drug Interactions between etravirine and meloxicam / rizatriptan
This report displays the potential drug interactions for the following 2 drugs:
- etravirine
- meloxicam/rizatriptan
Interactions between your drugs
meloxicam etravirine
Applies to: meloxicam / rizatriptan and etravirine
MONITOR: Coadministration with CYP450 2C9 inhibitors may increase the plasma concentration of meloxicam, which has been shown to be primarily metabolized by this isoenzyme. In a study of healthy volunteers, voriconazole, a weak CYP450 2C9 inhibitor increased the systemic exposure of meloxicam by 47% and prolonged the average meloxicam half-life by 51%.
MANAGEMENT: The potential for an interaction should be considered during concomitant use. If coadministration is required, monitor patients for NSAID-related side effects and toxicity including gastrointestinal bleeding or perforation. Dose adjustment of meloxicam may be warranted.
References (6)
- (2025) "Product Information. Symbravo (meloxicam-rizatriptan)." Axsome Therapeutics, Inc.
- (2025) "Product Information. Meloxicam (meloxicam)." Lupin Pharmaceuticals Inc
- (2024) "Product Information. Meloxicam (meloxicam)." Flamingo Pharma (UK) Ltd
- (2017) "Product Information. Meloxicam (meloxicam)." Teva Canada Limited
- (2024) "Product Information. Meloxicam (WGR) (meloxicam)." GM Pharma International Pty Ltd
- Hynninen VV, Olkkola KT, Bertilsson L, Kurkinen KJ, Korhonen T, Neuvonen PJ, Laine K (2009) "Voriconazole increases while itraconazole decreases plasma meloxicam concentrations" Antimicrob Agents Chemother, 53, p. 587-92
Drug and food interactions
etravirine food
Applies to: etravirine
ADJUST DOSING INTERVAL: Coadministration with food increases the oral bioavailability of etravirine. The mechanism is unknown. Compared to administration following a meal, the systemic exposure (AUC) to etravirine was decreased by about 50% when the drug was administered under fasting conditions. The types of meal studied (ranging from 345 kilocalories containing 17 grams fat to 1160 kilocalories containing 70 grams fat) did not appear to make a difference with respect to impact on etravirine bioavailability.
MANAGEMENT: Etravirine should always be administered following a meal.
References (1)
- (2008) "Product Information. Intelence (etravirine)." Ortho Biotech Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.